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PART A: LITERATURE REVIEW 
Objectives of the literature review 
- To briefly describe the trends for the global, sub-Saharan African, and South African burden of 
cardiovascular disease 
- To briefly describe the prevalence of acute coronary syndrome globally, in sub-Saharan Africa, 
and South Africa 
- To briefly review the various cardiac markers available for the diagnosis of acute coronary 
syndrome 
 
Literature search strategies, inclusion and exclusion criteria 
Searches were conducted to include relevant articles dated 2009 and later. Given a paucity of data, 
earlier publications were accepted for information related to Africa. Search engines used included: 
Pubmed/ Medline and Google Scholar. The following keywords were used: burden, ischaemic/ 
ischaemic, cardiovascular, Africa, Acute coronary syndrome, myocardial infarct, STEMI, NSTEMI, 
management, unstable angina, troponin, cardiac markers. The following phrases were also used 
during the Google Scholar search: Burden of cardiovascular diseases; Ischaemic heart disease in 
Africa; Acute coronary syndrome-global perspectives; Acute coronary syndrome in Africa; Definition 
of myocardial infarct; Management of non-ST elevation acute coronary syndrome; Unstable angina 
pectoris and more sensitive troponin assay; History of cardiac markers and diagnosis of acute 
coronary syndrome; Elevated troponin T in non-coronary diseases; Troponin T and non-coronary 
diseases; Cardiac markers; Interpretation of cardiac markers.   
Titles and abstracts were initially screened for relevance to the review and those deemed to have low 
relevance or poor external validity were excluded. Full-text copies of selected articles were extracted 
that fulfilled the inclusion criteria below. The reference sections of full-text papers were then 
evaluated further for papers not found through the initial search. Abstracts of these papers were then 
considered as well, and the process repeated until no more papers were found.   
High-quality evidence, including systematic reviews, was sought to address the aim and objectives. 
Papers were appraised against the relevant checklist from the Oxford Centre for Evidence-Based 
Medicine. (http://www.cebm.net/critical-appraisal/). A representation in tabular form of appraised 
papers is not required for the MMed and therefore was omitted. Very little data were available that 
directly addressed some parts of the aim and objectives – particularly with regards to literature related 
to the African context – and thus criteria were applied less stringently here. 
Inclusion criteria:  
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- Human studies 
- English language 
- Access to full text through institutional library 
- Date of publication: 2009 and later 
 
Introduction 
A global burden of cardiovascular disease 
The global burden of disease is shifting from communicable to non-communicable diseases (NCD) 
(1-3). Without an appropriate response to the spiralling epidemic, cardiovascular diseases and stroke 
will become the commonest causes of death and disability among NCDs by 2020 (1). The annual 
global death due to cardiovascular diseases will surpass HIV/AIDS by 2030 at the current rate of 
growth (4). Ischaemic heart diseases contributes most to cardiovascular disease-related mortality and 
disability-adjusted life years worldwide (3, 5, 6). Currently, more than 80% of cardiovascular related 
deaths occur in low- to middle-income countries (LMICs) (1, 6, 7).  
In LMICs, the increase of ischaemic heart diseases is driven by transformational economic and 
lifestyle changes (6, 8, 9). Risk factors for ischaemic heart disease includes: hypertension, raised 
serum cholesterol level, cigarette smoking, diabetes mellitus, poor physical activities and a high fat 
diet (7, 10, 11, 12, 13). Globally, these risk factors are similar according to the INTERHEART study 
(10). In many LMICs, ischaemic heart disease risk factors have been increasing over time. Brazil, for 
instance, tripled their ischaemic heart disease risk factors from 4.1% to 13.9% between 1975 and 1997 
(6). Systolic blood pressure (SBP) has increased in sub-Saharan Africa whilst decreasing in high 
income countries (HICs) (6). Consumption of sugary beverages, processed food and alcohol have 
been increasing dangerously matched with low level physical activity in both LMICs and HICs (6). 
Cardiovascular diseases, type 2 diabetes mellitus, cancer, chronic lung diseases and depression are the 
major NCDs in South Africa (SA) (8). When counting disability-adjusted life years, the World Health 
Organisation estimated that 28% of the burden of disease in SA was due to NCD in 2004, i.e. two to 
three times higher than in developed countries (8). Unfortunately, prevention of NCDs is overlooked 
as disproportionate attention is paid to higher prevalence burdens of HIV/AIDS and tuberculosis (12). 
The ACCESS (Acute Coronary Events- a Multinational Survey of Current Management Strategies) 
study found levels of initial care for acute of coronary syndrome (ACS) in SA, particularly in private 
hospitals, similar to HICs (4). Disappointingly, continuation of medications and lifestyle 
modifications were poor (10). Indeed, only 38% of patients quit smoking in SA compared to 42% in 
HICs (10). This attempt to understand the epidemiology of ACS in sub-Saharan Africa is 
commendable as studies are lacking in this area (9, 13).  
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In a nutshell, aggressive treatment and prevention of ischaemic heart diseases are yielding positive 
results in HICs (6). Conversely, limited access to adequate diagnostic and therapeutic options during 
and after an episode of ischaemic heart disease fuel particularly early-age death in LMICs (7, 12, 14). 
The same applies in South Africa where poorer communities in urban areas are more affected by 
NCDs (8). Indeed, the poorer regions of Cape Town have shown higher mortality secondary to NCDs 
compared to the more affluent regions in the south and north of the city (8). 
Acute coronary syndrome 
The approach to ACS diagnosis, besides the clinical examination and the electrocardiogram, involves 
the use of highly specific cardiac troponins for diagnosis and risk stratification (10, 15, 16). Assays 
use monoclonal antibodies to specifically detect either the cardiac troponin T or I (17- 19). Rising 
troponin levels are more specifically linked to cardiac necrosis, but elevated troponin levels may also 
be found in non-ACS conditions like heart failure, cardiomypathies, myocarditis, renal failure, 
tachyarrhythmias, pulmonary embolism, and strenuous exercises (17, 18, 20, 21). Current 
epidemiological knowledge about ACS relates overwhelmingly to studies performed in HICs (6). In 
the United States of America (USA), six million people are investigated annually for suspected ACS, 
among whom approximately a tenth are hospitalised with a confirmed diagnosis of ACS (19). In 
contrast to ACS patients from LMICs who tend to die younger, ACS patients from the USA live up to 
a median age of 68 years (5, 14, 22). Arguably, younger deaths resulting from ACS not only affects 
economic productivity, but also economic security for entire families.  
Sub-Saharan Africa’s rising ischaemic heart disease burden necessitates a holistic approach to focus 
not only on infectious diseases as was done in the past, but also on NCDs (8, 19). Much can be gained 
from local research to improve our understanding of cardiovascular disease. The study presented in 
part B is a small but significant study that contributes to the understanding of local trends in acute 
presentation, testing and outcomes of patients presenting with suspected ACS at a single public 
hospital. We hope that the findings of this study can aid local policy guidelines and collectively, with 
similar research, improve the acute care and outcome of patients suffering from ACS in South Africa. 
 
Definition of acute coronary syndrome 
Acute coronary syndrome represents a spectrum of clinical entities related to acute myocardial 
ischaemia (16). Based on the findings of a 12-lead electrocardiogram (ECG), ACS is grouped as 
follows (16, 22): 
- Acute ST elevation myocardial infarction (STEMI) that presents with new ST-segment elevation 
on the ECG. 
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- Non-ST elevation ACS (NSTEACS) that presents with new ST-segment depression, T wave 
changes, or no ECG abnormalities. NSTEACS comprises of the unstable angina and non-ST 
elevation myocardial infarction (NSTEMI).  
Unlike unstable angina, NSTEMI is a severe form of ischaemia resulting in myocardial damage and a 
subsequent release of biomarkers of myocardial injury (22). A release of biomarkers is not found with 
unstable angina (22). Furthermore, to avoid the different diagnoses associated to cardiac biomarkers 
release detected by ever sensitive laboratory tests, the third definition of acute myocardial infarction 
emphases the detection of a rise and/or fall of cardiac marker values together with other criteria to 
reach the diagnosis of acute myocardial infarction (16).    
 
Pathogenesis and pathophysiology of acute coronary syndrome 
Acute coronary syndrome has a heterogeneous aetiology resulting from five principal mechanisms 
(16, 23): plaque rupture (from atherosclerosis) with acute thrombosis, progressive mechanical 
obstruction, inflammation, secondary unstable angina due to e.g. severe anaemia, hyperthyroidism, 
etc., and dynamic obstruction (vasoconstriction).  Many of these mechanisms act concurrently, though 
the commonest mechanism remains atherosclerosis (23). In case of atherosclerosis, a thrombus can 
partially or completely occlude the coronary vessels, respectively resulting in different clinical 
presentations (23). Mostly the occlusion tend to be partial (or transient) resulting in myocardial 
ischaemia, but with no ST-segment elevation (unstable angina or NSTEMI) (23, 24).    
 
Epidemiology of acute coronary syndrome 
Worldwide, chest pain is a common cause of hospital admission (25). In Europe and the USA 
together, about 15-20 million people present to emergency centres (ECs) annually with chest pain 
(26). Yearly, about 1.4 million ACS patients are admitted into USA hospitals (27). Yet, only about 
10% of these end up with a diagnosis of STEMI (28). Acute coronary syndrome remains an important 
diagnosis in the USA with estimations of an episode of ACS every 25 seconds and an ACS-related 
death every minute (27).  Advances in acute care in high income regions has reduced complications of 
ACS by 50% (27)). In the United Kingdom, sustained preventive measures have dropped ACS 
incidence by 30% (29).  
Acute coronary syndrome has been steadily increasing in Africa. Earlier studies by Florentin revealed 
no evidence of myocardial infarction during autopsies in Uganda in 1963 (30). Similarly, referring to 
a study by Shaper, there was no evidence of myocardial infarction using clinical and laboratory 
criteria in Kenya in 1962 (30). Conversely, 2007 data from Senegal show an ACS incidence of 6.8% 
and rising (31). These changes reflect an epidemiological transition likely due to lifestyle 
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modifications (30).Showing no end to this debate Ntsekhe highlighted uncertainty about the 
contribution of ischaemic heart diseases to the burden of cardiovascular diseases in Africa in 2013 (4). 
It is fair to say that ACS management lags behind in Africa; despite the ACCESS study showing 
initial quality of care in private hospitals in South Africa, similar to worldwide performance (10, 12). 
Private care in South Africa makes up a small proportion of healthcare delivery in South Africa. 
Perhaps this point is more poignantly demonstrated in Kenya, where a 2014 study revealed that less 
than 50% of STEMI patients received  thrombolysis when indicated (32).  
The response to what appears to be a rising demand locally in ACS care has been fairly 
underwhelming. From the patchy literature available it appears that there are many small areas of 
excellence mixed with many more areas of less than excellence. This is unhelpful in a setting where 
patients have little choice regarding their healthcare options. We believe that more needs to be done to 
describe the local acute burden. 
 
Diagnosis of acute coronary syndrome 
General approach 
When left untreated, patients with ACS have a high risk for further cardiac complications (24, 28). 
These complications include: pulmonary oedema, rupture of the papillary muscles, rupture of the left 
ventricular free wall or the ventricular septum (23). For this reason, patients with ACS should be 
identified quickly for prompt management (23). Triage of patients presenting with chest pain should 
include clinical information (history and symptoms), a 12-lead ECG and biomarker testing (troponin 
is currently the preferred biomarker). This approach should promptly identify ACS patients and 
largely avoid the detrimental complications described earlier (10, 13, 33, 34). A strategic use of risk-
scoring systems in the consideration of the diagnosis of ACS is beneficial (35). Tools like the 
Thrombolysis In Myocardial Infarction (TIMI), the HEART (History, ECG, Age, Risk factors, 
Troponin) score and the Global Registry of Acute Coronary Events (GRACE) scores are well known 
(35).  
Only up to a quarter of patients suspected of suffering with ACS have a confirmed myocardial 
infarction; effective triage is therefore necessary to not only avoid inadvertent discharge of ACS 
patients but also unnecessary admissions that may lead to unnecessary investigations (33). Use of 
biomarkers, particularly those with a high sensitivity in diagnosing myocardial injury, is helping to 
close this gap (33). Unsurprisingly, the Thrombolysis in Myocardial Infarction-3 study showed that 
25% of unstable angina patients diagnosed using CK-MB, turned out to have a positive troponin 
assay, making unstable angina an uncommon diagnosis (36, 37). This is a notable point, as compared 
to unstable angina, NSTEMI is associated with an increased risk of mortality and adverse cardiac 
outcomes (20). An ideal biomarker should therefore be highly sensitive, specific and for which an 
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assay is simple, inexpensive, reproducible and rapid (20). Also, the use of the delta value as explained 
below is required in the third definition of acute myocardial infarction (16).  
Cardiac biomarkers 
During myocardial necrosis, compromise of the cellular membranes’ integrity releases a number of 
biomarkers (38). These include: myoglobin, creatine kinase (CK, particularly its CK-MB isoenzyme); 
cardiac troponin I, C and T; and lactate dehydrogenase (LDH) (20). Of these biomarkers, only CK-
MB and cardiac troponin I and T have been universally used to test for myocardial damage (20, 21).  
Others are used, but not consistently so. Generally, CK has poor specificity to rule in cardiac muscle 
damage, as it is also found in great quantities in the skeletal muscles (20). However, CK-MB 
isoenzyme offers better sensitivity and specificity mainly because only 1-3% of skeletal muscle CK is 
CK-MB (20, 38). CK-MB is also found in the intestine, diaphragm, uterus and prostate, which affects 
its accuracy (38). Despite this, CK-MB used to be the biomarker of choice until fairly recently but it 
has fallen out of favour with the introduction of more sensitive cardiac troponins (20).  
Troponins are cardiac and skeletal muscle regulatory proteins whose skeletal and cardiac isoforms are 
encoded by the same genes (20, 21). However, for troponin I and T, their cardiac and skeletal 
subforms are different (38).  Therefore, cardiac subforms of troponin have high myocardial specificity 
(18). This high specificity and an ever increasing sensitivity render troponins the biomarkers of 
choice.  
Kinetics of biomarkers (Table 1) 
The CK-MB level begins to rise three to four hours after the onset of myocardial necrosis and starts to 
fall by around 48-72 hours (20, 38). Cardiac troponin levels rise at the same time as CK-MB but fall 
much later, i.e. four to seven days for troponin I and 10-14 days for troponin T (38). 
Table 1: Cardiac marker levels (39) 
 Onset (hours) Peak (hours) Duration 
Troponin I 3-12 10-24 3-10 days 
Troponin T 3-12 12-48 5-14 days 
CK-MB 4-6 24 2-3 days 
 
Interpretations of biomarker results 
Manufacturers of laboratory troponin assay kits use different reference ranges for interpretation; these 
variations reflect differences in standardisation as well as different monoclonal antibodies that affect 
the sensitivity, specificity and precision of the assays (38). These variations are defined by the 
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percentile reference limits and the coefficient of variation (CV) (20, 21, 34). The percentile system 
describes the dispersion of test results among individuals, the upper normal percentile limit is 
considered to be the 99th percentile and any number greater than the 99th percentile is considered 
abnormal (38). The CV describes the variation of results obtained on the same assay. The CV 
determines the precision of the assay (21, 34). Its acceptable cut-off is 10% (20, 41).  At present, all 
troponin T assays are manufactured by one company, whereas troponin I are produced by a number of 
manufacturers (38). As a result, these troponin I assays differs on the 99th percentile and the CV10% 
(38).  
Over time, manufacturers have rendered assays able to detect increasingly lower levels of troponin 
(20, 21, 35). Whilst first generation assays had a myocardial infarct cut-off of 500 nanograms per litre 
(ng/L), most current assays (third generation) use a cut-off of 50 to 100 ng/L (35). Newer assays can 
detect a troponin leak as low as 3ng/L. The newer assays are termed high sensitivity assays and are 
able to detect troponin in more than 50% of normal individuals (35, 39). In practice, the ability to 
detect lower troponin T levels has a greater accuracy at ruling out an infarct early (35). Whilst the 
third generation assays require sampling at six hours from onset of symptoms (and a repeat sample six 
hours later), the latest high sensitivity troponin can be performed around three hours from onset of 
symptoms (also to be repeated at six hours) (20). Unfortunately, with increase in sensitivity, 
specificity is bound to suffer; specificity was reduced to 80-85% in contrast with earlier generation 
assays that had a specificity of around 97% (35). Serial testing with a delta value (variation between 
two consecutive tests) of equal to or more than 20% is therefore required to improve the specificity 
and rule out false positives (20, 40). Currently, delta testing underpins the interpretation of troponin 
testing as per the third definition of acute myocardial infarction.(16)  
Troponin use in sub-Saharan Africa 
Although the literature would suggest that the use of troponin as a diagnostic tool for ACS is 
commonplace, it is mostly in reference to HICs where that vast majority of related research is also 
generated. Very little is published about the use of troponin as a test for ACS within the African 
context.  Our search revealed only references to the use of troponin as part of larger studies, but none 
specifically described its use in any detail. Additionally some anecdotal evidence from South Africa 
suggests that older generation troponin assays are in use, some that predates the third definition of 
myocardial infarction. The use of newer generation troponin assays in HICs reduces the market for 
older ones and instead creates a market for these older (but cheaper) generations of troponin assays in 
LMICs (communication Dr. Richard Body, 02/12/2016). The problem with using an assay that does 
not have the accuracy to describe myocardial infarction as per the third definition is that it cannot be 
used in any algorithm that depends on the third definition. This substantially limits its diagnostic 
value.   




Summary and recommendations 
Acute coronary syndrome is a major cause of morbidity and mortality worldwide.  It has also become 
a serious concern in sub-Saharan Africa of late as estimates suggests an upward trend in prevalence.  
The diagnosis of ACS is underpinned by an appropriate history, an ECG and appropriate testing.  
Currently troponin testing is considered the gold standard provided it fulfils the criteria as per the 
third definition of myocardial infarction, but there appears to be anecdotal concern about the use of 
older generation troponin assays with lower diagnostic accuracy in lower income settings. Specific 
research is required to better describe the overall demographics and prevalence of ACS in sub-
Saharan Africa and its various regions, to describe the quality of care and outcomes locally as 
compared to internationally, and to describe the validity of earlier generation diagnostic testing among 
suspected ACS patients locally. 
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The global burden of disease is shifting from communicable to non-communicable diseases including 
acute coronary syndrome. There is comparatively less data available regarding acute coronary 
syndrome in Sub-Saharan Africa compared to elsewhere. Clinical findings, ECG changes and 
troponin testing forms the mainstay of diagnosis. Many resource limited settings still use dated 
troponin assays. The aim of this study was to describe the diagnosis, prevalence and outcome of acute 
coronary syndrome at an urban, public emergency centre in Cape Town, South Africa where an older 
assay is in use. 
Methods 
A retrospective, cross-sectional design was used to enrol participants. Comparisons were made 
between the diagnosis, outcome and troponin result (as per the Roche cardiac reader). Findings were 
presented as figures and proportions, and associations were tested using the Chi2-test. 
Results 
Nine hundred and sixty-nine patients were included, from which 40 (4%) were excluded due to lack 
of clinical records. Two hundred and fifty-six patients were diagnosed with acute coronary syndrome, 
from which only 54 were troponin positive (Chi2 = 22.1, p<0.001). However, 197 (76.9%) acute 
coronary syndrome diagnoses turned out to be unstable angina. 
Conclusions 
Prevalence of ACS was low, with a high proportion of presenting patients indicated as not having 
disease.  However, the prevalence of unstable angina was higher than current trends where more and 
more sensitive troponin tests are in use. Despite the limitations of the study, assay accuracy should be 
considered an important variable, striking a balance between patient safety and cost effectiveness. 
More research is required to explore this further. 
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Main text of article 
 
Describing the diagnosis, outcome and prevalence of acute coronary syndrome 
when investigated with the Roche cardiac reader at a regional, public South 
African emergency centre 
 
Background 
The global burden of disease is shifting from communicable to non-communicable disease; without 
intervention, the morbidity due to cardiovascular diseases will supersede human immunodeficiency 
virus/acquired immunodeficiency syndrome (HIV/AIDS) by 2030 (1- 3). Despite a dearth of 
cardiovascular diseases knowledge in sub-Saharan Africa, more than 80% of cardiovascular-related 
deaths are estimated to occur in low- to middle-income countries (LMICs) (1- 5). Acute coronary 
syndrome (ACS) is the commonest cause of death and disability among cardiovascular diseases (3, 5, 
6). Aggressive treatment and prevention in high-income countries already yields positive results, 
hence these treatment reference standards are also considered in LMICs (5). However, the 
epidemiology, precise patterns and outcomes of ACS management in Africa are poorly documented 
(2, 7, 8). In LMICs, South Africa included, an increase of ACS appears to be due to transformational 
economic and lifestyle changes (5, 8, 9). In the INTERHEART study, one of the larger African 
studies, ischaemic heart disease risk factors were similar worldwide (i.e. hypertension, raised 
cholesterolaemia, diabetes mellitus, cigarette smoking, poor physical activities and high fat diet) and 
smaller studies have replicated these findings (4, 7- 11). Moreover, cardiovascular diseases appear to 
claim younger lives in LMICs, which in turn impacts productivity (4, 10, 12). In contrast, addressing 
cardiovascular diseases has not matched its growth and solutions remain elusive in LMICs, mainly 
due to poor availability and/or quality of the resources required for its diagnosis and care (5, 10, 13).  
Acute coronary syndrome includes ST-elevation myocardial infarction (STEMI) and non-ST-
elevation ACS (NSTE-ACS) (14). The latter comprises unstable angina and non-ST-elevation 
myocardial infarction (NSTEMI) (14, 15). Besides the clinical and electrocardiogram (ECG) findings, 
the use of highly sensitive cardiac troponins has become the reference standard for the diagnosis of 
myocardial infarction, alongside risk stratification for ACS (14- 17). Assays use monoclonal 
antibodies to specifically detect either the troponin T or I. The accepted reference standard for the 
upper reference limit of a troponin assay is currently considered at the 99th percentile with a 
coefficient of variability of less than 10% (14- 16, 18- 20). Importantly, as newer troponin assays 
continue to become more and more sensitive, and thus able to detect lower and lower levels of 
biomarker, the diagnosis of unstable angina has become fairly uncommon; perhaps only about 5-10% 
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of ACS cases (21, 22, 23). Unsurprising, the Thrombolysis in Myocardial Infarction-3 study showed 
that 25% of unstable angina patients diagnosed using CK-MB, turned out to have a positive troponin 
assay (22). This is a notable point, as compared to unstable angina, NSTEMI is associated with an 
increased risk of mortality and adverse cardiac outcomes (18). To counter the reduction of specificity 
associated with a higher sensitivity, and thus reducing the proportion of false positives, serial troponin 
assays are also recommended; significant changes of troponin levels usually equal or more than 20% 
from the baseline over a specified timeframe, implicate myocardial infarction (14, 19, 24, 25).    
Although very little is known about the use of troponin testing in LMICs, it is reported anecdotally 
that due to cost restrictions, many LMIC facilities still make use of older troponin assays that predate 
current reference standards.  The study site is one of those facilities.  It is unclear how the use of less 
sensitive troponin assays with a wider coefficient of variability stack up to an acceptably, safe 
diagnosis as incorrect interpretation of results could result in unintended harm to patients (13, 17, 24).  
Therefore, understanding how the diagnostic test for ACS relates to the eventual diagnosis and 
outcome is an important quality consideration.   
The aim of this study was to describe and compare the troponin result, exit diagnosis and outcome 
(admission, transfer, discharge or death), as well as the prevalence of ACS, in patients in whom ACS 
was suspected on first assessment at a regional, public emergency centre (EC) where an older assay 
was being used.   
 
Methods  
The study was performed using a retrospective, cross-sectional design. It was conducted at Mitchells 
Plain Hospital EC, Cape Town, South Africa. The Mitchells Plain catchment area includes a low- to 
middle-income suburban area within Cape Town. It houses around a third of a million people, mainly 
of mixed race (91%) (26). About 10% of the Mitchells Plain population has no income and 40.5% 
have an annual income equivalent to between US$ 2700 and 11000 (26). The EC sees around 3800 
patients per month. Although exact figures are unknown, anecdotally, ACS is considered to have an 
above average prevalence in this area. The hospital does not have a cardiology service or angiography 
suite, and access to cardiology services, including angiography, is through Groote Schuur Hospital, a 
tertiary, referral hospital, 23km away. Even so, primary coronary intervention is not consistently 
available, even at Groote Schuur Hospital.  
Study participants were identified via the National Health Laboratory Services as patients who have 
had troponin T testing performed at the EC over a four-month period between 1st July and 31st 
October 2015. At Mitchells Plain hospital, all EC medical doctors requests troponin T test upon 
clinical suspicion of ACS. At Mitchells Plain hospital, clinicians freely use history taking, ECG 
findings, troponin T testing and any risk scoring tool to reach the diagnosis of ACS.  The Study 
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participants’ identification via the laboratory service allowed access to folder numbers and hence 
tracking of the clinical record. Information obtained from the clinical record included: age, gender, 
exit diagnosis (ACS/ not ACS on exiting the hospital following either discharge, transfer or death), 
disposition outcome (discharge from EC, admission to Mitchells Plain Hospital, transfer from hospital 
to Groote Schuur Hospital or death during admission at Mitchells Plain hospital EC) and documented 
risk factors (hypercholesterolaemia, hypertension, diabetes mellitus, smoking, positive family history 
and obesity). The exit diagnosis were taken from the clinical notes as described on death, or discharge 
or transfer from hospital.  The ECG was not specifically evaluated as part of the study protocol.  This 
is further discussed in the limitations section.  Exclusions were for missing diagnosis and outcome 
variables. Patients were not excluded for missing risk factor variables.  
The troponin T assay used during the data collection period was the Roche CARDIAC® T 
Quantitative assay, or Cardiac Reader. This assay has a coefficient of variability greater than 10% at 
the 99th percentile for the upper reference limit. For the purpose of this study, the troponin T results 
were dichotomised (positive/ negative) according to local guidance. The test is considered positive if 
the level is above 100ng/L and negative if below 50ng/L. The assay only provides a range for a 
troponin T result between 50 and 100ng/L. If this range is reported, a repeat test would usually be 
performed at six to 12 hours after the first to determine the final result. If the repeat troponin T assay 
remains between 50 and 100ng/L, the result is considered negative; it is considered positive if it 
subsequently rises above 100ng/L. Where multiple troponin T tests were performed during a single 
admission, the first troponin T result, six to 12 hours after symptom onset (or admission in case 
symptom onset is not described) was used to determine the result. This interpretation mimics the use 
of the test locally. 
A sample size of 384 consecutive subjects meeting the inclusion criteria was required. The sample 
size calculation assumed a 50% proportion of positive clinical diagnosis (with α=0.05 and β=0.8). 
Microsoft Excel and SPSS were used for analysis. Numerical data (e.g. age) were expressed as mean 
and standard deviation (SD). Categorical data (troponin T results, disposition, diagnosis at disposition 
and risk factors) were expressed as frequencies. To compare troponin T results (positive/negative) to 
either the disposition diagnosis (ACS/not ACS), or the disposition (survival to discharge from EC, 
survival to discharge from Mitchells Plain Hospital ward (admission), survival to transfer, and death 
during admission at Mitchells Plain Hospital EC) the Chi²-test was used. A p-value of less than 0.05 
was considered statistically significant. To compare the disposition diagnosis (ACS/not ACS) to ACS 
risk factors and troponin result, odds ratios were calculated using univariate logistic regression. 
Ninety five percent confidence intervals are presented where appropriate as a further measure of 
precision. The study received ethics approval from the Health Research Ethics Committee at 
Stellenbosch University (Reference: S16/02/029). 
 




A sample of 969 datasets were collected of which 40 were excluded due to insufficient clinical 
information. The mean age was 58 years (SD ± 14). There were 420 (45.2%) men included in the 
sample. Figure 1 provides a summary of the study’s main findings. Outcome observations included 
911 datasets as 18 patients were discharged after refusing further hospital treatment. 
 
 
Figure 1: Summary of study findings 
A diagnosis of ACS was significantly associated with a positive troponin assay when compared to a 
diagnosis of ACS associated with a negative troponin assay (Chi2=22.1, p<0.001). Similarly, a 





















































Stellenbosch University  https://scholar.sun.ac.za
25 
 
diagnosis other than ACS was significantly associated with a negative troponin assay when compared 
to a diagnosis other than ACS with a positive troponin assay (Chi2=8.9, p<0.01). Unstable angina was 
diagnosed in 197 (76.9%) patients with an ACS diagnosis. Unstable angina represents 82.8% (197 
patients out 238) of all NSTE-ACS patients. Eighteen patients with STEMI underwent troponin T 
testing, 5 had a negative troponin T result. Significantly more patients were discharged following a 
negative troponin assay result versus a positive result (Chi2=27.9, p<0.001), whilst significantly more 
patients were referred following a positive result (Chi2=57.7, p<0.001).  Admission to a ward and 
mortality showed no statistical difference irrespective of the troponin result (p=0.54 and p=0.06 
respectively).   
Table 1 describes the number and proportion of comorbidities for the study population and Table 2 
describes the odds ratios from the univariate logistic regression analysis. 
Table 1: Summary records of risk factors among study participants. Proportions are a function of all 
cases included in the sample (n=929). 
Risk factor Risk factor documented 
as present, n (%) 
Risk factor not 
documented, n (%) 
Hypercholesterolaemia  346 (37.2) 452 (48.7) 
Hypertension  709 (76.3) 2 (0.2) 
Diabetes mellitus  365 (39.3) 5 (0.5) 
Smoking  401 (43.2) 270 (29.0) 
Family history  62 (6.7) 859 (92.4) 
Obesity  75 (8.1) 844 (90.8) 
 
Table 2: Logistic regression to evaluate association of a positive troponin T assay and the risk factor 
variables with an ACS diagnosis 





Troponin T positive 4.24 2.73 - 6.57 <0.001 
Hypercholesterolaemia 1.92 1.63 - 2.26 <0.001 
Hypertension 1.92 1.32 - 2.78 <0.001 
Smoking 1.25 1.05 - 1.49 0.01 
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Diabetes mellitus 1.11 0.83 - 1.48 0.47 
 
Discussion 
Even though ACS was significantly associated with a positive troponin assay result, there was 
undoubtedly a substantial number of patients diagnosed with ACS that had negative troponin T 
results; in other words, unstable angina (197 out of 256 patients; 76.9%). This proportion was 
substantially higher than the 5 - 10% Lim et al. described (21, 22). Critical assessment of the final 
diagnosis among ACS also showed that unstable angina represented 82.8% of all NSTE-ACS patients. 
Intuitively, the reliance to clinical and ECG findings may explain the high proportion of unstable 
angina. The troponin T assay at study site was seemingly a weak help in discriminating between the 
different types of NSTE-ACS. Indeed, newer, more and more sensitive troponin tests are expected to 
reduce the proportion of unstable angina to the benefice of NSTEMI. Admittedly, the present study is 
not designed to assess the validity of the troponin T assay at the study site, but the proportion of 
unstable angina is an eye-opener not easily to be ignored. With an unfavourable cardiac adverse 
events outlook, NSTEMI has far reaching implications compared to unstable angina and has to be 
diagnosed on time (18). Ultimately, it is important to thwart the overuse of the diagnosis unstable 
angina.  
 
From an EC perspective, the value of a troponin test also lies in its ability to rule-out disease as the 
vast majority of patients presenting with a suspected diagnosis of ACS turn out not to have the 
disease. However, the findings of this study suggest the contrary with a sizable proportion of troponin 
negative patients diagnosed as NSTE-ACS and admitted. Clearly, clinical vigilance may have 
informed admissions as similar admission trends were observed regardless of the troponin T test 
results.  What is concerning is that local clinicians’ interpretations of troponin results are likely based 
on, and influenced by current international reference standards. Another disadvantage of the troponin 
T assay at the study site is its inability to calculate the delta value from indeterminate values as 
recommended (14, 19). Hypothetically, patients that are diagnosed as non-ACS on the basis of a 
flawed negative troponin result may come to harm. Likewise, over-diagnosis of ACS due to 
compensation for a flawed troponin assay will also be associated with an increased risk of harm (e.g. 
anticoagulation, missed alternative diagnosis, etc.).  
Given the significant associations with a number of reported risk factors, it is likely that an ACS 
diagnosis significantly relied on clinical acumen and an interpretation of the history in addition to 
troponin findings. The current study did not evaluate for the ECG patterns commonly associated with 
ACS due to restricted study resources, a design limitation, but rather relied on the exit diagnosis 
which usually involved a specialist physician or emergency physician. Regarding risk factors, the 
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findings of this study join the INTERHEART study as they show an association of ACS to a number 
of known risk factors. It was interesting to note that diabetes was equally common among ACS and 
non-ACS patients. Conversely, it is disappointing that documentation of some risk factors, i.e. family 
history of cardiovascular events and obesity, was found to be poor. This is particularly important 
given that clinicians were seemingly applying more weight to the clinical examination and ECG 
findings during the ACS work-up. 
Overall, ACS was found in about a quarter (256 out of 929 patients) of the study population. 
However, this doesn’t necessarily represent the prevalence of ACS at Mitchells Plain hospital. Indeed 
many patients with STEMI would be treated promptly without requesting a troponin T test. 
Surprisingly, a few patients with STEMI (18 patients) had a troponin T testing in our study 
population. In these cases, prompt management of STEMI ensued regardless of troponin T results that 
were available only later. Some of these STEMI had a negative troponin T result. Without an in-depth 
analysis, particularly the inclusion of findings at the referral academic cardiology unit, negative 
troponin T STEMI may have most likely reflected the result of a too early test and/or a less sensitive 
assay. Another less likely reason may have been a misdiagnosis. However, requesting a troponin T 
test for an obvious STEMI (by ECG and clinical presentation) is not cost effective. Also, in the study 
population, usage of hospital services was higher among ACS patients as they were more likely to be 
admitted or referred to the academic hospital compared to non-ACS.  
Although the study findings were anticipated, the extent of the findings were unexpected. The 
findings opened up questions about the limitations of the diagnostic process within the study setting, 
the validity of the test used and how these findings will impact on local ACS care. As a retrospective 
study, it relied heavily on the quality of data collected from patient files. The troponin interpretation 
protocol also has limitations, specifically with regards to serial investigations surrounding the result 
provided as a range. Other limitations of this study are: non-randomisation of the study sample and 
non-reporting of the 30-day major adverse cardiovascular events as well as the association of ECG 
findings. However, this study is one of the very first studies describing ACS in this lower-middle 
income population.  Randomisation should certainly be considered in future studies.  Including the 
ECG evaluation in the study protocol would have added an additional dimension to the evaluation of 
the NSTE-ACS diagnosis, but this would have had to be done independently to be of value.  The 
study team did not have the resources to include ECG evaluation and therefore made use of the exit 
diagnosis to define whether ACS existed or not.  Future studies should certainly consider independent 
interpretation of ECGs.  This would improve scrutiny of the clinical diagnosis and thus provide a 
deeper understanding of how an ACS diagnosis is made in the local setting. 
Considering the findings of this study and its limitations, further studies may be recommended to 
address the following issues: the contribution of the ECG findings to the diagnosis of ACS, the 30-day 
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major adverse cardiac events associated to ACS, the validity of the troponin T assay used in this study 
and the underlying diagnoses among non-ACS patients.   
 
Conclusion 
Despite internationally accepted reference standards, some facilities operating in LMICs continue to 
make use of troponin assays that are unable to reliably detect troponin rises. Emergency care 
clinicians working in LMICs are reminded of the value of a thorough history and physical 
examination when ACS is suspected; that a negative troponin should be considered truly negative 
only after close evaluation of a patient’s symptoms, the history and ECG findings; and that serial 
troponin testing is not necessarily a panacea. The latter result should always be interpreted with due 
caution especially when presented with a range instead of an absolute value. Evaluation of the 
diagnostic process in the study setting, particularly focusing on the contribution of ECG findings, 
should be considered for future research. Wider ACS research in the region, particular with regards to 
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A descriptive study of the definitive diagnosis and outcome of patients 
tested for suspected acute coronary syndrome with the troponin T test at 



















Supervisors:  Rachel L Allgaier: Division of Emergency Medicine, University of Stellenbosch 
                        Moosa Kalla: Department of Emergency Medicine, Mitchells Plain Hospital 
                        Stevan Bruijns: Division of Emergency Medicine, University of Cape Town 
  
Stellenbosch University  https://scholar.sun.ac.za
34 
 
A descriptive study of the definitive diagnosis and outcome of patients 
tested for suspected acute coronary syndrome with the troponin T test at 
Mitchells Plain Hospital emergency centre 
I- PURPOSE OF THE STUDY 
This study aims to review the current clinical and demographic data as well as the final 
diagnosis and disposition outcome of patients tested for suspected acute coronary syndrome 
(ACS) with the troponin T test presenting to Mitchells Plain Hospital Emergency Centre 
(EC). This descriptive study is primarily projected to inform the establishment of an ACS 
registry at Mitchells Plain Hospital EC. Ultimately, this knowledge will contribute to increase 




The global burden of disease is shifting from communicable to non-communicable 
diseases (1). By 2020, among the non-communicable diseases, cardiovascular diseases 
and stroke will be the commonest causes of death and disability. The annual global death 
due to cardiovascular diseases will reach 24 million people by 2030 without intervention 
(1). Currently, more than 80% of cardiovascular related deaths occur in low-to-middle-
income countries (1). ACS is the commonest cause of death and disability among patients 
with cardiovascular diseases (2). It basically comprises two entities: ST-elevated 
myocardial infarction and non-ST-elevated ACS (3, 4).  
Current epidemiological knowledge about ACS relates mainly to high-income countries. 
There are only a few studies involving low-to-middle-income countries also revealing the 
increasing burden of cardiovascular diseases there (5). The INTERHEART study showed 
that the risk factors for cardiovascular disease remain similar worldwide (5). The major 
risk factors of cardiovascular diseases are: raised blood pressure, raised cholesterol levels, 
cigarette smoking, diabetes mellitus, physical activity and high fat diet (5). 
Approach to ACS diagnosis, besides the examination and the electrocardiogram, involves 
the use of highly specific cardiac troponins for the diagnosis and risk stratification of 
ACS (5, 6). Assays use monoclonal antibodies to specifically detect either the cardiac 
troponin T or I (6-8). Rising troponin T levels are more specifically linked to cardiac 
necrosis (8). However, elevated troponin T levels may also be found in non-ACS 
conditions like heart failure, cardiomypathies, myocarditis, renal failure, 
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tachyarrhythmias, pulmonary embolism, strenuous exercises (7, 8).  In the United States 
of America (USA), 6 million people are investigated annually for suspected ACS (9). 
Approximately a tenth of these patients are hospitalised with actual diagnosis of ACS (9). 
Also in the USA, patients with ACS have a median age of 68, in contrast to patients with 
ACS in low-to-middle-income countries who tend to be younger along thus affecting 
economic productivity (2, 4).  
Furthermore the tenacity of burden of infectious diseases, coupled with the acceleration 
of non-communicable diseases, specifically in Sub-Saharan Africa, has led to a 
substantial burden of disease (9).  Anecdotally a lot of research focuses on infectious 
disease, with less focus on non-communicable diseases such as ACS.  Understanding 
local trends in presentation, testing and outcomes of patients presenting with suspected 
ACS will aid local policies and ultimately improve the acute care involved in managing 
ACS. 
2- RESEARCH QUESTION 
Among patients tested for suspected acute coronary syndrome with the troponin T test at 
Mitchells Plain Hospital EC, what were the final diagnoses and disposition (discharge 
from EC, inpatient stay, transfer and death)? 
3- OBJECTIVES 
For the purposes of the objectives, disposition outcome refers to the following variables:    
-      survival to discharge from EC,  
- survival to discharge from Mitchells Plain hospital ward,  
- survival to transfer and  
- death during admission at Mitchells Plain hospital.   
The objectives of this study are: 
a. To compare the Troponin T results (positive/negative) to the disposition diagnosis 
(ACS/not ACS). 
b. To compare the Troponin T results (positive/negative) to the disposition outcome. 
c. Sub-objectives are:  
- To compare the disposition diagnosis (ACS/not ACS) to the disposition 
outcome 
Stellenbosch University  https://scholar.sun.ac.za
36 
 
- To compare the Troponin T results (positive/negative) to risk factors 
(hypercholesterolemia, hypertension, diabetes mellitus, smoking, positive 
family history and obesity) documented during admission.  
- To compare the disposition diagnosis (ACS/not ACS) to risk factors 
(hypercholesterolemia, hypertension, diabetes mellitus, smoking, positive 
family history and obesity) documented during admission. 
 
III- METHODOLOGY 
1- STUDY DESIGN 
This design will be a descriptive, retrospective, cross-sectional study. 
2- CHARACTERISTICS OF THE STUDY POPULATION AND AREA 
The study population will be drawn from patients presenting to the Mitchells Plain 
Hospital EC; these patients mainly resides in the Mitchells Plain and surrounding suburbs 
of Cape Town (10). According to the 2011 Census, 310485 people lived in Mitchells 
Plain.  Among those, 91% are of mixed ancestry, 7% are Black African, and the rest 
Asians and Whites (10). The 25 to 64 years old age group predominates and represents 
50% of the population (10). Unemployment stands at 24% (10). The prevalence of ACS is 
not known in these areas, though it is perceived to be high.   
Mitchells Plain Hospital EC has four adult beds in the adult resuscitation area. There is a 
paediatric resuscitation bed in a paediatric emergency suite. There are 13 adult beds in the 
trolley area, 9 chairs in the nebulisation room and a large number of chairs for the adult 
and paediatric minor ailment areas. Currently, Mitchells Plain Hospital EC is estimated to 
see 3600 to 3800 patients per month.  The exact proportion of ACS patients from the 
overall cohort is not known but is also perceived to be high.  Local treatment at Mitchells 
Plain Hospital EC tends to be the norm for ACS; patients are managed through the 
internal medicine department once diagnosed and admitted from the EC.  Access to 
cardiology services, including angiography, is through Groote Schuur Hospital.   The 
latter is not a primary service as far as ACS is concerned. 
3- RECRUITMENT AND ENROLMENT 
Study participants will be identified through the National Health Laboratory Services 
(NHLS) by searching for patients who have had troponin T testing performed at the 
Mitchells Plain Hospital EC during the period 1st July to 31st December 2015. A sample 
size of 384 consecutive subjects meeting the inclusion criteria (see below) will be 
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collected. The sample size calculation assumed a 50% proportion of positive clinical 
diagnosis (with α=0.05 and β=0.8). Given the retrospective nature of the data collection 
and bearing in mind that electronic record will be used to gather data (approximately 90% 
capture), it is possible (though not expected) that the study period may have to be 
extended to achieve this sample. This will be done by extending the study period until the 
required sample size has been achieved. The following patients that have had a troponin T 
testing performed for suspected ACS will be excluded from the study: subjects with 
missing electronic records and those with lacking demographic information (age and 
gender), the final diagnosis and/or outcome disposition.  It is accepted that risk factors 
may be variably reported.  This is further discussed in the limitations section and is the 
reason risk factors are only included as sub-objectives. 
4- RESEARCH PROCEDURES AND DATA COLLECTION METHODS 
Research process is visually described in Figure 1. All the study subjects will be 
identified through NHLS records and selected as consecutive troponin T tests over the 
study period.  The hospital numbers associated with the NHLS outputs will then be used 
to access further variables (Table 1) through the electronic record.  All patients’ notes are 
captured electronically and stored in the electronic records.   
If multiple troponin T tests have been performed during a single admission, only the 
troponin T test performed 12 hours post symptoms onset will be used for negative results 
or any positive results within 6 to 12 hours of symptoms onset. For the purpose of this 
study the troponin T result will be dichotomised.  The troponin T test result is positive if 
the level is above 100 and negative if the level is below 50. For troponin T test values 
between 50 and 100, trends and clinical presentations are used to determine the final 
diagnosis. Where the symptoms onset is not stated, the time of presentation to Mitchells 
Plain Hospital EC will be assumed as the beginning of symptoms. 
A sample size check will be performed after the selection of subjects with troponin T 
testing during the study period and the addition of relevant demographic and clinical data 
described in recruitment and enrolment above. The sample will then be anonymised by 
substituting the folder numbers with a unique study number.  This will be done prior to 
data analysis starting. 
5- DATA SAFETY AND MONITORING 
Data form NHLS and electronic record will be captured in a Microsoft Excel spreadsheet. 
Names, addresses and other personal identifiable information other than the folder 
number will not be collected. Folder numbers will be replaced with study numbers once 
the database has been established and cleaned as described above. Only after 
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anonymising of the database has been completed will analysis start. Data will be kept in a 





Figure 1: Research procedure and data collection 
  
Identification of subjects 
through NHLS databank of 
troponin T test request from 
EC over the study period
Access patient electronic 
record using subject hospital 
number obtained from NHLS
Applying exclusion criteria 
and removal of duplicates
sample size check and adding 
additional datasets if needed
Anonymising of final sample 
and start analysis
Record variables depicted in 
Table 1
Record troponin T test date 
and result as well as the time 
of request  for each subject
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Table 1 Variables to be included in the data collection 
 Folder number 
 Age 
 Gender 
 Date and time of symptom onset 
 Date and time of presentation to MPH EC 
 Date and time of troponin request 
 Troponin T result 
 Diagnosis (ACS/ not ACS) 
 Risk factors (hypercholesterolemia, hypertension, diabetes mellitus, smoking, 
positive family history and obesity) 
 Date and time of disposition from MPH EC 
 Disposition outcome: 
 Survival to discharge from EC,  
 Survival to discharge from Mitchells Plain hospital ward,  
 Survival to transfer and  
 Death during admission at Mitchells Plain hospital) 
 
6- DATA ANALYSIS 
Microsoft Excel and SPSS will be used for analysis. Numerical data (e.g. age) will be 
summarised as mean or median (central tendency) with standard deviation (SD) or 
interquartile range used to define spread. Categorical data (troponin T results, disposition, 
diagnosis at disposition and risk factors) will be expressed as frequencies.  To compare 
troponin T results (positive/negative) to either the disposition (survival to discharge from 
EC, survival to discharge from Mitchells Plain hospital ward, survival to transfer and 
death during admission at Mitchells Plain hospital) or the disposition diagnosis (ACS/not 
ACS), relative risks of disposition or disposition diagnosis will be calculated and 
compared using the Chi²-test.  To compare the disposition diagnosis (ACS/not ACS) to 
ACS risk factors, and odds ratio of risk factors will be calculated and compared using the 
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Chi²-test.  During Chi²-testing, a p value of less than 0.05 will be considered statistically 
significant. Ninety five percent confidence intervals will be presented where appropriate. 
 
IV- ETHICAL CONSIDERATIONS 
1- DESCRIPTION OF RISKS AND BENEFITS 
The findings of this study are expected to raise the awareness and to improve ACS 
identification and management within the resource limited settings on the Cape Flats, 
specifically Mitchells Plain. Furthermore, its findings will contribute to the feasibility of 
establishing an ACS registry for the Mitchells Plain Hospital drainage area and, 
ultimately, the broader Western Cape Province. Conversely, particularly if a considerable 
number of troponin T testing results are negative, foreseen risks of misinterpretation may 
lead to reduce troponin T testing requests for cost-effectiveness.   
2- INFORMED CONSENT PROCESS 
Given the retrospective nature, data collection and analysis plan of the study a request 
will be made for a waiver of consent. Permission to pursue research will be obtained from 
the Human Research Ethics Committee of the University of Stellenbosch as well as 
Mitchells Plain Hospital through the Western Cape Provincial Government Department of 
Health/ National Health Research Database.   
3- PRIVACY AND CONFIDENTIALITY 
Data will be kept in a password protected file on an access controlled, password protected 
computer. The data will not include subjects’ identities, e.g. names and national identity 
numbers. Folder numbers will be replaced with study numbers once the database has been 
established and cleaned as described above (data safety). Only after anonymising of the 
database will analysis start. 
4- REIMBURSEMENT FOR PARTICIPATION 
The data collection in this study does not involve any direct contact with study subjects. 
No re-imbursement will be required. 
5- EMERGENCY CARE AND INSURANCE FOR RESEARCH-RELATED INJURIES 
This study is retrospective and does not require any intervention on study subjects. No 
research-related injuries are expected to occur. 
 
V- LIMITATIONS 
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The following limitations may be forseen: 
- Reliance on the quality of pre-recorded data in a retrospective study, 
particularly the recording of ACS risk factors.  
- Conclusions will reflect findings related to a specific area and may not be 
generalised. 
 
VI- DISSEMINATION OF FINDINGS PLAN 
The findings of the study will be assimilated and published in a medical peer review journal. 
Mitchells Plain Hospital will receive a copy of the dissertation to inform its management of 
the outcome of the study 
VII- PROJECT TIMELINE 
Table 2: Project timeline 



































































 X X                 









       X X X          
Data 
analysis 
         X X X X X      
Transcri              X X X X X  








                  X 
 
 
VIII- RESOURCES UTILISATION 
The following resources will be required to gather information and finalise the present study: 
NHLS database, electronic record, transportation and a computer. The NHLS database and 
the electronic record will be accessed using the Mitchells Plain Hospital computer system. 
Preliminarily, Mitchells Plain Hospital has verbally agreed to allow the use of its database and 
computer. Final agreement will be given after official application. 
 
IX- BUDGET 
Budget in Table 3 will be covered by own funds. 
Table 3: Study budget 
ITEMS AMOUNT 
Transportation R 1000 
Language editor  R 100 
Statistician fee R 500 
Stationary R 500 
TOTAL R 2100 
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